Vivacta Biotechnology Secures Over $50M in Series A and A+ Financing

Vivacta Biotechnology, a Shanghai-based biotech firm, successfully concludes Series A and A+ funding rounds, raising more than $50 million to support the advancement of clinical trials, regulatory activities, team expansion, and global operations for its core product, GT801.